
Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?
Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.
Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.
The debate has been
A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.